Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.
You may also be interested in...
Novartis Exjade Clears FDA As First Oral Chelating Agent
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
Novartis Exjade Clears FDA As First Oral Chelating Agent
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
Novartis' Exjade Recommended For Approval Under Broader Indication
FDA's Blood Products Advisory Committee agreed that data for the oral chelating agent from primarily thalassemia patients may be extrapolated to transfusional hemosiderosis.